TWST Relative Valuation
TWST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TWST is overvalued; if below, it's undervalued.
Historical Valuation
Twist Bioscience Corp (TWST) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.97 is considered Undervalued compared with the five-year average of -18.30. The fair price of Twist Bioscience Corp (TWST) is between 1501.38 to 1512.26 according to relative valuation methord. Compared to the current price of 30.21 USD , Twist Bioscience Corp is Undervalued By 97.99%.
Relative Value
Fair Zone
1501.38-1512.26
Current Price：30.21
97.99%
Undervalued
-18.29
PE
1Y
3Y
5Y
Trailing
Forward
-22.53
EV/EBITDA
Twist Bioscience Corp. (TWST) has a current EV/EBITDA of -22.53. The 5-year average EV/EBITDA is -18.00. The thresholds are as follows: Strongly Undervalued below -44.22, Undervalued between -44.22 and -31.11, Fairly Valued between -4.88 and -31.11, Overvalued between -4.88 and 8.23, and Strongly Overvalued above 8.23. The current Forward EV/EBITDA of -22.53 falls within the Historic Trend Line -Fairly Valued range.
-17.02
EV/EBIT
Twist Bioscience Corp. (TWST) has a current EV/EBIT of -17.02. The 5-year average EV/EBIT is -15.96. The thresholds are as follows: Strongly Undervalued below -40.58, Undervalued between -40.58 and -28.27, Fairly Valued between -3.65 and -28.27, Overvalued between -3.65 and 8.66, and Strongly Overvalued above 8.66. The current Forward EV/EBIT of -17.02 falls within the Historic Trend Line -Fairly Valued range.
4.34
PS
Twist Bioscience Corp. (TWST) has a current PS of 4.34. The 5-year average PS is 15.70. The thresholds are as follows: Strongly Undervalued below -15.75, Undervalued between -15.75 and -0.02, Fairly Valued between 31.43 and -0.02, Overvalued between 31.43 and 47.15, and Strongly Overvalued above 47.15. The current Forward PS of 4.34 falls within the Historic Trend Line -Fairly Valued range.
57.46
P/OCF
Twist Bioscience Corp. (TWST) has a current P/OCF of 57.46. The 5-year average P/OCF is 149.61. The thresholds are as follows: Strongly Undervalued below -1555.93, Undervalued between -1555.93 and -703.16, Fairly Valued between 1002.38 and -703.16, Overvalued between 1002.38 and 1855.15, and Strongly Overvalued above 1855.15. The current Forward P/OCF of 57.46 falls within the Historic Trend Line -Fairly Valued range.
172.39
P/FCF
Twist Bioscience Corp. (TWST) has a current P/FCF of 172.39. The 5-year average P/FCF is -24.58. The thresholds are as follows: Strongly Undervalued below -74.72, Undervalued between -74.72 and -49.65, Fairly Valued between 0.49 and -49.65, Overvalued between 0.49 and 25.56, and Strongly Overvalued above 25.56. The current Forward P/FCF of 172.39 falls within the Strongly Overvalued range.
Twist Bioscience Corp (TWST) has a current Price-to-Book (P/B) ratio of 3.80. Compared to its 3-year average P/B ratio of 3.50 , the current P/B ratio is approximately 8.54% higher. Relative to its 5-year average P/B ratio of 5.46, the current P/B ratio is about -30.52% higher. Twist Bioscience Corp (TWST) has a Forward Free Cash Flow (FCF) yield of approximately -3.25%. Compared to its 3-year average FCF yield of -9.64%, the current FCF yield is approximately -66.34% lower. Relative to its 5-year average FCF yield of -7.58% , the current FCF yield is about -57.17% lower.
3.48
P/B
Median3y
3.50
Median5y
5.46
0.00
FCF Yield
Median3y
-9.64
Median5y
-7.58
Competitors Valuation Multiple
The average P/S ratio for TWST's competitors is 1054.27, providing a benchmark for relative valuation. Twist Bioscience Corp Corp (TWST) exhibits a P/S ratio of 4.34, which is -99.59% above the industry average. Given its robust revenue growth of 17.91%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TWST decreased by 36.36% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -11.61 to -19.27.
The secondary factor is the Revenue Growth, contributed 17.91%to the performance.
Overall, the performance of TWST in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Twist Bioscience Corp (TWST) currently overvalued or undervalued?
What is Twist Bioscience Corp (TWST) fair value?
How does TWST's valuation metrics compare to the industry average?
What is the current P/B ratio for Twist Bioscience Corp (TWST) as of Aug 06 2025?
What is the current FCF Yield for Twist Bioscience Corp (TWST) as of Aug 06 2025?
What is the current Forward P/E ratio for Twist Bioscience Corp (TWST) as of Aug 06 2025?